Transforming Trauma | Emerging Therapies and Interventions in Post-Traumatic Stress Disorder Treatment Market

According to Future Market Insights, the Post-Traumatic Stress Disorder (PTSD) Treatment Market Sales would grow at a 5% CAGR between 2023 and 2033. By 2033, the global market for post-traumatic stress disorder (PTSD) therapy is expected to reach US$ 27.37 billion. The market's growth might be attributed to the increased prevalence of PTSD globally.

According to the National Centre for PTSD, approximately 7-8% of the US population will develop PTSD at some point in their lives, with greater percentages among military veterans and persons who have experienced sexual assault or other types of trauma. The COVID-19 pandemic has also been highlighted as a possible cause of PTSD, with healthcare workers, first responders, and people immediately impacted by the virus being especially vulnerable.

In addition, there is a growing emphasis on using digital therapies and other non-pharmacological techniques to treat PTSD. For example, virtual reality exposure treatment (VRET) has shown potential results in reducing PTSD symptoms by allowing clients to address their trauma in a secure and controlled environment. Limbix and Psious, for example, are developing VRET platforms to treat PTSD and other mental health problems.

Competitive Landscape

Key players in the post-traumatic stress disorder (PTSD) treatment market are: Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceutical Development & Commercialization, Inc., Bionomics Limited, Merck KGaA, Pfizer Inc., Aurobindo Pharma Limited, GlaxoSmithKline plc, Viatris Inc., Jubilant Pharmova

Browse Detail Summary@ https://www.futuremarketinsights.com/reports/post-traumatic-stress-disorder-treatment-market

Key Segments Profiled in the Post-Traumatic Stress Disorder (PTSD) Treatment Industry Survey

By Drug Class:

  • Antidepressants
  • Anti-anxiety Drugs
  • Antipsychotics
  • Other Drug Classes

By Distribution Channel:

  • Retail Pharmacies
  • Online Pharmacies

Comments

Post a Comment

Popular posts from this blog

Autosomal Dominant Polycystic Kidney Disease Treatment Market is Likely to Witness Steady Growth by 2033

According to a recent Future Market Insights report, the global Autosomal Dominant Polycystic Kidney Disease Treatment market demand will grow at a 5.97% CAGR from 2023 to 2033, reaching an estimated value of US$ 2,140 million. One of the primary drivers of market expansion is the availability of special regulatory designations, with an increase in Autosomal Dominant Polycystic Kidney Disease Treatment trials also projected to add to the industry's progress. Furthermore, regulatory authorities are expected to introduce and approve new Autosomal Dominant Polycystic Kidney Disease Treatment drugs, which will drive industry growth. Drug companies profit from market exclusivity for a set amount of time, as well as clinical trial tax benefits and treatment assistance, which helps to increase the market. Technological developments and the development of a wide range of medications are also projected to push market expansion, allowing physicians to better aid patients with Autosomal Domi
Read more

Targeted Therapies for Sandhoff Disease | Assessing the Global Market Landscape

Image
The global Sandhoff Disease Therapeutics Market Size is expected to be worth US$ 10 million in 2023 and US$ 17.91 million by 2033, with a CAGR of 6% from 2023 to 2033. From 2018 to 2022, the Sandhoff Disease Treatments market increased at a 4% CAGR. According to the most recent studies, Sandhoff sickness is a rare disorder that affects 1 in 1,000,000 people. The rising demand for these medications is projected to spur the discovery of novel therapies, propelling the market forward in the coming years. Gene therapy is being investigated as a potential treatment for Sandhoff disease. The therapy restores the ability to break down GM2 ganglioside by delivering a functional copy of the missing enzyme into the patient's cells. This has the potential to reduce or stop disease progression while also improving patient quality of life. Key Takeaways from the Market Study   The Sandhoff Disease Therapeutics market increased at a 4% CAGR from 2018 to 2022. From 2023 to 2033, the global Sandh
Read more

A Safer Tomorrow | Emerging Trends in Hospital-Acquired Infection Control Market

Image
According to Future Market Insights' recently released Hospital-acquired Infection Control Market analysis report, global Hospital-acquired Infection Control sales in 2023 are expected to be US$ 6.5 billion. The market is expected to increase at a CAGR of 7% between 2023 and 2033, reaching $12.7 billion by 2033. Hospitals and intensive care units are predicted to create significant income in the market, with a CAGR of 7.6%. The occurrence of hospital-acquired infections, increasing proportion of surgical procedures, growing geriatric population and increasing prevalence of chronic diseases, technological advancements in sterilisation equipment, and growing awareness of environmental and personal hygiene are the key factors driving the Hospital-acquired infection control market. The increased use of e-beam sterilisation, as well as the reintroduction of ethylene oxide sterilisation, is predicted to increase demand for hospital-acquired infection management. The percentage of treatm
Read more